#China #Shanghai #Global Expansion #Fosun Pharma #Innovative Drugs

Fosun Pharma Delivers Impressive Interim Results for 2026

On August 25, 2026, Fosun Pharma, also known by its stock codes 600196.SH and 02196.HK, unveiled its interim financial results for the first half of 2026. The company experienced a remarkable revenue increase of RMB 20.442 billion, signifying a year-on-year rise of 4.75%, or even 7.17% when adjusted for constant exchange rates. Notably, profit attributable to shareholders saw an impressive growth of 19.09%, amounting to RMB 1.144 billion, reflecting an enhancement in the quality of earnings. Additionally, net cash generated from operating activities surged to RMB 2.424 billion, showcasing a year-on-year growth of 13.59.

Innovation and Globalization as Growth Engines

Fosun Pharma's success has been anchored on two pivotal factors: innovation and globalization. Revenue sourced from innovative drugs reached RMB 4.911 billion, marking a significant year-on-year rise of 13.84%. This revenue now represents 33.21% of the pharmaceutical segment's total, a 2.17 percentage point improvement compared to the previous year. Furthermore, the company's revenue from international markets outside of mainland China amounted to RMB 6.379 billion, reflecting a robust growth of 16.45% year-on-year. This indicates a positive trend in the Group's overall revenue mix.

Focused Therapeutic Areas and Accelerating Clinical Progress

Fosun Pharma remains committed to prioritizing core therapeutic areas such as oncology, immunology and inflammation, as well as neurodegenerative diseases. Moreover, the company is branching out into cardiovascular, renal, and metabolic diseases, anti-infectives, and rare diseases, among others. By employing an open-innovation approach, which melds their in-house research and development with two-way licensing and funding models, the company is briskly advancing clinical applications for its innovative products.

In the first half of 2026, Fosun Pharma’s total R&D investment rose to RMB 3.247 billion, a 25.66% year-on-year increase. Of this investment, a significant 81.61% was directed at innovative drug development, with a focus on promising products such as HLX43, HLX22, and FXR0906. During this period, 20 indications for 7 innovative drugs achieved regulatory approval for market launch both domestically and abroad.

Major Approvals and New Indications

Among the noteworthy advances, Han Si Zhuang (Serplulimab) received Chinese approval for its use in perioperative gastric cancer treatment, addressing a significant global clinical requirement. Furthermore, the drug has already been introduced in around 50 countries, with reimbursement available in key markets including the UK, Germany, and Italy. Another of Fosun Pharma's flagship products, Han Bei You (Pertuzumab), continues to thrive in the market following successful approvals in both the EU and China.

Additionally, the company has been proactive in expanding its market presence: the NDA application for SAF-189, an ALK inhibitor for non-small cell lung cancer, has been accepted by NMPA. This reflects Fosun Pharma's ongoing commitment to streamlining the regulatory process for its cutting-edge products.

Diversified Clinical Trials and Innovations

As part of its long-term growth strategy, Fosun Pharma has instituted international multi-center trials for key pipeline candidates across various countries, significantly widening its research scope. The pipeline candidate HLX43, aimed at multiple solid tumors, is being recognized for its promising clinical efficacy and favorable safety profile.

The company also made strides in immunology and inflammation with incremental pipeline assets. Phase IIb trials for FXS6837 and FXS7553 have commenced, targeting prominent conditions such as IgA nephropathy and non-cystic fibrosis bronchiectasis.

Strategic Partnerships and Global Manufacturing

Fosun Pharma’s international reach includes collaborations with companies like Eisai and Abbott to strategically license innovative products. These partnerships deepen the global penetration of its innovative assets, positioning the company favorably in the worldwide pharmaceutical landscape.

Supporting these ambitions, Fosun Pharma has been enhancing its manufacturing capabilities to comply with international regulations. Gland Pharma, a subsidiary that recently secured FDA approval, will significantly contribute to ensuring quality and faster delivery to diverse global markets.

Conclusion: A Promising Future

The interim results underscore Fosun Pharma’s resilience and strategic adaptability amidst evolving industry challenges. With a strong focus on global expansion, innovation in core therapeutic areas, and multi-faceted growth strategies, Fosun Pharma is poised to enhance its market standing and ensure the delivery of innovative healthcare solutions worldwide.

As stated by Chen Yuqing, Chairman of Fosun Pharma, the company is committed to navigating through uncertainties with strategic clarity to maintain steady revenue growth. Could the successes in these interim results be just the beginning for Fosun Pharma's journey of innovation and internationalization? Time will tell.